KentWilliamMouwMD

PubMed

• 1 citations
  The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives.
  Amy J Wisdom, Christopher A Barker, Joe Y Chang, Sandra Demaria, Silvia Formenti, Clemens Grassberger, Fabiana Gregucci, Bradford S Hoppe, David G Kirsch, Ariel E Marc...> ;International Journal of Radiation Oncology, Biology, Physics. 2024 Apr 1
• Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.
  Yuzhen Zhou, Vincent D D'Andrea, Surish P Shanmugam, Isabella Stelter, Dag R Stormoen, Rea Chroneos, Timothy Hanlon, Ilana Epstein, Raie T Bekele, Filipe F L Carvalho,...> ;European Urology. 2024 Mar 23
• Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.
  Huffman, B., Singh, H., Ali, L., Horick, N., Wang, S., Hoffman, M., Metayer, K., Murray, S., Bird, A., Abrams, T., Biller, L., Chan, J., Meyerhardt, J., McCleary, N., ...> ;Journal for Immunotherapy of Cancer. 2024 Jan 25
• Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
  Galsky, M., Daneshmand, S., Izadmehr, S., Gonzalez-Kozlova, E., Chan, K., Lewis, S., Achkar, B., Dorff, T., Cetnar, J., Neil, B., D'Souza, A., Mamtani, R., Kyriakopoul...> ;Nature Medicine. 2024 Jan 19
• SABR Today . . . and Tomorrow?
  Tran, P., Mouw, K.> ;International Journal of Radiation Oncology, Biology, Physics. 2024 Jan 1
• 1 citations
  Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
  Kamran, S., Zhou, Y., Otani, K., Drumm, M., Otani, Y., Wu, S., Wu, C., Feldman, A., Wszolek, M., Lee, R., Saylor, P., Lennerz, J., Van Allen, E., Willers, H., Hong, T....> ;Clinical Cancer Research. 2023 Dec 15
• ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
  Yuzhen Zhou, Judit Börcsök, Elio Adib, Sophia C Kamran, Alexander J Neil, Konrad Stawiski, Dory Freeman, Dag Rune Stormoen, Zsofia Sztupinszki, Amruta Samant, Amin Nas...> ;Science Advances. 2023 Nov 24
• DNA repair deficiency and the immune microenvironment: A pathways perspective.
  Yuzhen Zhou, Kent W Mouw> ;DNA Repair. 2024 Jan 1
• 9 citations
  Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
  Galsky, M., Daneshmand, S., Izadmehr, S., Gonzalez-Kozlova, E., Chan, K., Lewis, S., Achkar, B., Dorff, T., Cetnar, J., Neil, B., D'Souza, A., Mamtani, R., Kyriakopoul...> ;Nature Medicine. 2023 Nov 1
• 1 citations
  Clinical Outcomes of De Novo Versus Relapsed Early Metastatic Testicular Seminoma Treated With Contemporary Radiation Therapy.
  Daniel B Rosen, Anushka Ghosh, Andrzej Niemierko, Clair J Beard, Praful Ravi, Alok Tewari, Christopher Sweeney, Richard J Lee, Philip Saylor, Neil Martin, Jason A Efst...> ;International Journal of Radiation Oncology, Biology, Physics. 2024 Mar 1
• 4 citations
  Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
  Kendrick Yim, Kevin Melnick, Sarah L Mott, Filipe L F Carvalho, Affan Zafar, Timothy N Clinton, Matthew Mossanen, Graeme S Steele, Michelle Hirsch, Natalie Rizzo, Chin...> ;Urologic Oncology. 2023 Nov 1
• 1 citations
  Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
  Justin Hwang, Xiaolei Shi, Andrew Elliott, Taylor E Arnoff, Julie McGrath, Joanne Xiu, Phillip Walker, Hannah E Bergom, Abderrahman Day, Shihab Ahmed, Sydney Tape, All...> ;Clinical Cancer Research. 2023 Jul 14
• Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
  Patrick J Hensley, Roland Seiler, Harry Herr, Kent W Mouw, Gopa Iyer, Lars Dyrskjøt, Roman Nawroth, Peter Goebell, Bernd Schmitz-Drager, Tilman Todenhofer, Peter C Bla...> ;Urologic Oncology. 2023 Jul 1
• 24 citations
  CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
  Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie,...> ;Nature Communications. 2023 Jan 17
• Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer.
  Kent W Mouw, Atish D Choudhury> ;Cancer Treatment and Research. 2023 Jan 1
• 34 citations
  Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
  Amin H Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W Akl, Pier Vitale Nuzzo, Tarek H Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Hab...> ;Cancer Cell. 2022 Oct 10
• 1 citations
  Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes.
  Matthew Mossanen, Amin H Nassar, Samantha M Stokes, Nieves Martinez-Chanza, Vivek Kumar, Pier Vitale Nuzzo, David J Kwiatkowski, Judy E Garber, Catherine Curran, Dory ...> ;Clinical Genitourinary Cancer. 2022 Dec 1
• Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-in...
  Filipe L F Carvalho, Matthew Mossanen, Eliezer M Van Allen, Kent W Mouw> ;European Urology. 2022 Nov 1
• 7 citations
  PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer.
  Kasia M Dillon, Raie T Bekele, Zsofia Sztupinszki, Timothy Hanlon, Shahrzad Rafiei, Zoltan Szallasi, Atish D Choudhury, Kent W Mouw> ;NPJ Precision Oncology. 2022 Jun 29
• 1 citations
  Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy.
  Hae Lin Cho, Vedang Murthy, Kent W Mouw, Anthony V D'Amico, Paul L Nguyen, Jonathan E Leeman, Edward Christopher Dee> ;The Prostate. 2022 Aug 1
• 10 citations
  Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
  Matthew Mossanen, Filipe L F Carvalho, Vinayak Muralidhar, Mark A Preston, Brendan Reardon, Jake R Conway, Catherine Curran, Dory Freeman, Sybil Sha, Guru Sonpavde, Mi...> ;European Urology. 2022 May 1
• 4 citations
  Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.
  Guru P Sonpavde, Kent W Mouw, Matthew Mossanen> ;Journal of Clinical Oncology. 2022 Apr 20
• 13 citations
  Magnetic Resonance-Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort.
  Jonathan E Leeman, Daniel N Cagney, Raymond H Mak, Mai Anh Huynh, Shyam K Tanguturi, Lisa Singer, Paul Catalano, Neil E Martin, Anthony V D'Amico, Kent W Mouw, Paul L ...> ;Advances in Radiation Oncology. 2022 Mar 6
• 7 citations
  loss overrides PARP inhibitor sensitivity driven byloss in prostate cancer.
  Chenkui Miao, Takuya Tsujino, Tomoaki Takai, Fu Gui, Takeshi Tsutsumi, Zsofia Sztupinszki, Zengjun Wang, Haruhito Azuma, Zoltan Szallasi, Kent W Mouw, Lee Zou, Adam S ...> ;Science Advances. 2022 Feb 18
• 25 citations
  Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer.
  Shaoming Zhu, A-Hong Ma, Zheng Zhu, Elio Adib, Ting Rao, Na Li, Kaiyuan Ni, Veera Chandra Sekhar Reddy Chittepu, Rao Prabhala, Juan Garisto Risco, David J. Kwiatkowski...> ;Journal for Immunotherapy of Cancer. 2021 Nov 1
• Join now to see all

Journal Articles

• Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic  
  Kent W Mouw, Paul L Nguyen, JAMA Oncology